checkAd

    Editas Medicine (Seite 12)

    eröffnet am 07.06.16 19:34:31 von
    neuester Beitrag 05.02.24 21:13:31 von
    Beiträge: 596
    ID: 1.233.158
    Aufrufe heute: 0
    Gesamt: 42.246
    Aktive User: 0


    Beitrag zu dieser Diskussion schreiben

     Durchsuchen
    • 1
    • 12
    • 60

    Begriffe und/oder Benutzer

     

    Top-Postings

     Ja Nein
      Avatar
      schrieb am 07.03.18 21:58:23
      Beitrag Nr. 486 ()
      ATH ist durch!
      Avatar
      schrieb am 03.03.18 15:37:34
      Beitrag Nr. 485 ()
      Antwort auf Beitrag Nr.: 57.175.398 von belliora am 03.03.18 09:12:04
      Zitat von belliora: Wenn das alles so kommt, dann müsste der Kurs eines Tages in Anlehnung an die FB-Kapitalisierung 250 mal höher stehen....sehr sehr ambitioniert....und wir sind alles steinreich.:rolleyes:


      das wird höchst wahrscheinlich auch nicht so kommen.
      ist halt die typische, reisserische Überschrift der schreibenden Zunft.
      Sonst wird ja keiner mehr aufmerksam auf irgendwas bei der allgemeinen
      Reiz/News-Überflutung heut zuTage.

      Ich kann mir aber einen Buyout so um die 50 bis 80 USD vorstellen
      und damit wäre ich persönlich zufrieden:)

      S.
      Avatar
      schrieb am 03.03.18 09:12:04
      Beitrag Nr. 484 ()
      Antwort auf Beitrag Nr.: 57.175.218 von Schaeffi am 03.03.18 08:24:17Wenn das alles so kommt, dann müsste der Kurs eines Tages in Anlehnung an die FB-Kapitalisierung 250 mal höher stehen....sehr sehr ambitioniert....und wir sind alles steinreich.:rolleyes:
      1 Antwort
      Avatar
      schrieb am 03.03.18 08:24:17
      Beitrag Nr. 483 ()
      3 Growth Stocks That Could Put Facebook's Returns to Shame
      https://finance.yahoo.com/news/3-growth-stocks-could-put-134…
      2 Antworten
      Avatar
      schrieb am 03.03.18 08:22:01
      Beitrag Nr. 482 ()
      Here’s Why Gilead Sciences' Jump Into Gene Editing Is Important
      https://uk.finance.yahoo.com/news/why-gilead-sciences-apos-j…

      Schade SGMO hab ich nicht mehr, hätte man behalten sollen:cry:
      die Haben zwar die ältere/teurere Genediting Methode, sind aber dadurch naturgemäß in
      der Entwicklung viel weiter. Das war für GILD anscheinend der Grund für die
      Partnerschaft.

      Campbell: Right. Sangamo has been working on this zinc finger technology for about 20 years. It's pretty much the primary patent holder of this technology. That differentiates itself a little bit from CRISPR Cas9. Our listeners are probably asking themselves, why didn't Gilead go out and buy Editas or CRISPR Therapeutics (NASDAQ: CRSP) or something like that to get involved in CRISPR Cas9? Obviously, there's been a lot of attention spent by media on CRISPR Cas9, what's this zinc finger thing all about? I think Gilead basically looked at it and said, we know there's a risk of off-target when you're doing gene editing, and that can be kind of scary. You don't want to have a situation where you jump in with CRISPR Cas9, which is a relatively new technology, and it turns out that there's a lot of off-target gene editing that goes along in using it. Since zinc finger has been researched for some 20-some odd years by Sangamo, it appears that Gilead Sciences thinks, we know better what we're getting into from a safety standpoint. I think Sangamo's zinc finger nucleases have been used in over 100 patients in clinic. CRISPR Cas9 is only looking to get into clinic this year.


      :eek:
      SGMO EDIT CRSP NTLA
      ONCE BLUE CLLS
      und die 2 Big Ones
      CELG GILD
      :eek:

      S.

      Trading Spotlight

      Anzeige
      Rallye II. – Neuer Anstoß, News und was die Börsencommunity jetzt nicht verpassen will…mehr zur Aktie »
      Avatar
      schrieb am 25.02.18 19:35:50
      Beitrag Nr. 481 ()
      CRISPR will save lives - and technology can't come soon eough


      https://www.smh.com.au/technology/crispr-will-save-lives-and…

      Ich bin nach wie vor der Meinung, dass die CRSPR Technologie
      in einigen Jahren nicht mehr weg zu denken ist und wir uns Mitten
      in einem BioTech/ Pharma / Agroscience Umbruch befinden.

      Kann mir durchaus weiter Übernahme die nächsten Wochen im Sector vorstellen.

      GILD / KITE mit neuem Partner SGMO (hab ich leider zu früh verkauft)
      GILD mit CRSP T. hat sich wohl (noch) nicht gezeigt

      CELG / JUNO mit Partner EDIT


      let´s begin the "GeneEditing - Race"

      S.
      Avatar
      schrieb am 21.02.18 20:26:31
      Beitrag Nr. 480 ()
      schöner Spike heute

      vermutlich wegen

      https://www.fool.com/investing/2018/02/15/3-great-acquisitio…

      und

      $EDIT Anybody see the discussion about EDIT on CNBC? It sounds like they were discussing potential royalty percentages for CRISPR

      aus ST geklaut :p

      S.
      Avatar
      schrieb am 16.02.18 22:27:13
      Beitrag Nr. 479 ()

      https://sciencebusiness.net/news/expected-green-light-gene-e…

      "Expected green light for gene editing in agriculture a big moment for researchers, says MEP

      Italy’s Paolo De Castro shares his vision of agriculture’s future and how cuts to the EU farm budget would endanger it
      By Éanna Kelly

      Photo: Bigstock

      An expected decision by the European Court of Justice (ECJ) to exempt gene editing technologies from the strict laws governing genetically modified organisms in Europe would put scientists on the leading edge of a new global research race, says Italian member of the European Parliament Paolo De Castro.

      The court’s opinion, presented last month by the advocate general, could have far-reaching consequences for new breeding techniques, using CRISPR–Cas9, that can remove negative traits from a plant’s genetic code and promote herbicide-resistant traits. The advice is not binding but is usually followed by ECJ judges, who are expected to make a final decision later this year.

      “Researchers have been waiting a long time for this, and it’s a very important development for Europe,” De Castro, vice-chair of the Parliament's committee on agriculture and rural development, told Science|Business. “I’m happy; I’ve been saying that we need this decision for a long time.”

      Opponents of the technique say that meddling with DNA is potentially perilous. However, because gene-editing does not necessarily involve the transfer of genes between species, as happens in GMOs, the MEP argues that the practice is safe for public health, and good for the environment.

      “We don’t want GMOs,” De Castro said. “But this new breeding technique has nothing to do with ‘Frankenstein food’. It’s about accelerating a natural process, and it opens an important window of opportunity for research.”

      De Castro gives the example of research in Italy to kill off destructive diseases in grapevines. “It could mean our farmers would reduce their use of pesticides in fields by one million tonnes,” he said.

      Such a breakthrough technology depends on continued support from the EU budget, De Castro added.

      Farmers in the MEP’s constituency are fighting tooth and claw to maintain €59-billion per year, common agricultural policy (CAP) budget, some 40 percent of the EU budget. Before the next round of budget negotiations, it appears the knife is out for CAP, as Brussels faces a cash crunch after the departure of the UK in 2019.

      Budget battle

      De Castro acknowledges that it is almost certain that farm funding will get chopped. “We are ready to ask for more money but I’m quite sure the budget will fall,” he said. “If the cut is 5-7 per cent, we can manage that.”

      EU leaders have agreed that the overall post-2020 budget should focus more on defence, research and competitiveness, leaving De Castro, a son of farmers and a two-term minister of agriculture, concerned that a totem EU policy will lose out.

      “All the transformation we’ve made in 50 years is in large part due to the CAP,” he said. “We needed more food after the war. We’ve had incredible success, going from starving to surplus. If we forget this policy, we forget 10 million farmers.”

      Making the CAP fit

      At the very least there should be a new round of reform for the flawed CAP model, which pays farmers based on how much land they have, a system that benefits the richest. Around 80 per cent of the money goes to only 20 per cent of farms.

      The digital revolution is helping make production in farms more efficient, said De Castro, but he acknowledges that the CAP has not always encouraged innovation. Similarly, rewards under the policy for farmers who protect wildlife habitats, open their land to the public, plant woodlands and safeguard the landscape, have been criticised.

      The European Court of Auditors in November found that the programme’s rural development system is plagued by implementation delays. “Greening is a nice idea but we need better results,” De Castro said.

      For once, it may not be straightforward to count on France as the bulwark of the pro-CAP camp. Emmanuel Macron has said there should be discussion about reforming the policy “without taboos” – fighting words in a country that is the largest net beneficiary of the EU farm budget.

      De Castro finds Macron’s position on farming difficult to decode. “We like him very much, he’s a European, he played Ode to Joy before La Marseillaise when he won the election, but I don’t think he has a good knowledge of common agricultural policy,” De Castro said."
      Avatar
      schrieb am 12.02.18 22:10:06
      Beitrag Nr. 478 ()
      die Strunzbude mal wieder auf Abwegen....es lebe Crispr T.
      Avatar
      schrieb am 09.02.18 18:44:09
      Beitrag Nr. 477 ()
      Heute noch black friday und danach erst recht der black monday...so wie bei jedem crash...?
      • 1
      • 12
      • 60
       DurchsuchenBeitrag schreiben


      Investoren beobachten auch:

      WertpapierPerf. %
      -1,06
      +0,33
      +0,06
      +0,17
      -1,09
      -1,11
      +1,68
      +1,81
      -2,32
      -0,77
      Editas Medicine